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Role of the β-D-endoglucuronidase heparanase in septic 
cardiomyopathy 
Background: Septic cardiomyopathy (SC) is frequently recognized in patients with septic shock 
and indicates a worse prognosis. Disturbed calcium homeostasis characterizes the 
pathophysiology of SC. Heparanase is an endogenous immune modulator, however the role of 
heparanase in SC is fully unknown. 
Objective: To evaluate (i) activity of heparanase in patients with septic shock, (ii) role of 
heparanase gene single nucleotide polymorphisms (SNPs) on heparanase activity, (iii) role of 
heparanase in the induction of SC, and (iv) therapeutic effects of heparanase inhibition on SC in 
mice. 
Methods: (i) After permission (EK:206_09), serum heparanase activity was measured in patients 
with septic shock (n=20) and after abdominal surgery (n=9) at day 1 (D1) and 2 (D2) after 
onset/surgery. (ii) SNPs (rs4693608; rs4364254) were determined in these patients. (iii) Murine 
cardiomyocytes (HL-1 cells) were stimulated with heparanase (15mU/ml) for 24h. After permission 
(70/7348), C57BL/6J-mice (n=8 per group) were challenged with heparanase (1U, i.v.), 
lipopolysaccharide (LPS) and peptidoglycan (PepG) (6mg/kg, 1mg/kg; i.p.) or vehicle (150µl 
saline). 1h after LPS/PepG-challenge mice were treated with a specific heparanase inhibitor (N-
desulfated re-N-acetylated heparin; 500µg; i.v.) or vehicle. Serum heparanase activity and ejection 
fraction (EF) was quantified 24h later and signaling events on calcium hemostasis in were 
investigated by immunoblot in HL-1 cells and heart tissue. Statistics: 1-way or 2-way-ANOVA and 
Bonferroni test (significance p<0.05). 
Results: Heparanase activity at D1 and D2 was significantly higher in patients with septic shock 
compared to surgical control patients. In patients with heparanase genotypes CT-GG, TT-GG, CT-
AG or CT-AA (n=11), heparanase activity significantly decreased at D2 compared to D1. Patients 
with heparanase genotypes TT-AA or TT-AG (n=9) showed no significant difference in 
heparanase activity between D1 and D2. Stimulation of HL-1 cells with heparanase significantly 
reduced the expression of sarcoplasmic calcium ATPase (SERCA2) and phosphorylation of the 
SERCA2-modulator phospholamban. When compared to vehicle-challenged animals, 
heparanase or LPS/PepG-challenge resulted in a significantly reduced EF, a significantly elevated 
heparanase activity, and a significant reduction of cardiac SERCA2 expression and 
phospholamban phosphorylation. Inhibition of heparanase subsequent to LPS/PepG-challenge 
resulted in a significantly attenuated reduction of EF, a significantly attenuated elevation of 
heparanase activity, and a significantly attenuated reduction of SERCA2-expression and 
phospholamban phosphorylation compared to untreated animals. 
Conclusions: Heparanase activity is elevated during septic shock in a genotype-dependent 
manner. The therapeutic inhibition of heparanase attenuates SC. Thus, heparanase may serve 
as a potential therapeutic target to treat SC in men. 
 
 
